S&P 500   4,440.39 (-0.19%)
DOW   34,706.33 (-0.17%)
QQQ   371.40 (-0.42%)
AAPL   146.14 (-0.47%)
MSFT   297.67 (-0.63%)
FB   347.84 (+0.54%)
GOOGL   2,831.75 (+0.26%)
TSLA   762.69 (+1.20%)
AMZN   3,400.18 (-0.46%)
NVDA   219.18 (-2.51%)
BABA   145.75 (-3.60%)
NIO   35.43 (-1.61%)
CGC   13.96 (-4.12%)
GE   104.04 (+1.05%)
MU   74.37 (+0.45%)
AMD   105.20 (-0.89%)
T   27.20 (+0.04%)
F   13.89 (+1.31%)
ACB   5.97 (-2.93%)
DIS   175.29 (-0.54%)
PFE   44.08 (-0.25%)
BA   221.33 (+0.10%)
BAC   42.18 (+1.18%)
S&P 500   4,440.39 (-0.19%)
DOW   34,706.33 (-0.17%)
QQQ   371.40 (-0.42%)
AAPL   146.14 (-0.47%)
MSFT   297.67 (-0.63%)
FB   347.84 (+0.54%)
GOOGL   2,831.75 (+0.26%)
TSLA   762.69 (+1.20%)
AMZN   3,400.18 (-0.46%)
NVDA   219.18 (-2.51%)
BABA   145.75 (-3.60%)
NIO   35.43 (-1.61%)
CGC   13.96 (-4.12%)
GE   104.04 (+1.05%)
MU   74.37 (+0.45%)
AMD   105.20 (-0.89%)
T   27.20 (+0.04%)
F   13.89 (+1.31%)
ACB   5.97 (-2.93%)
DIS   175.29 (-0.54%)
PFE   44.08 (-0.25%)
BA   221.33 (+0.10%)
BAC   42.18 (+1.18%)
S&P 500   4,440.39 (-0.19%)
DOW   34,706.33 (-0.17%)
QQQ   371.40 (-0.42%)
AAPL   146.14 (-0.47%)
MSFT   297.67 (-0.63%)
FB   347.84 (+0.54%)
GOOGL   2,831.75 (+0.26%)
TSLA   762.69 (+1.20%)
AMZN   3,400.18 (-0.46%)
NVDA   219.18 (-2.51%)
BABA   145.75 (-3.60%)
NIO   35.43 (-1.61%)
CGC   13.96 (-4.12%)
GE   104.04 (+1.05%)
MU   74.37 (+0.45%)
AMD   105.20 (-0.89%)
T   27.20 (+0.04%)
F   13.89 (+1.31%)
ACB   5.97 (-2.93%)
DIS   175.29 (-0.54%)
PFE   44.08 (-0.25%)
BA   221.33 (+0.10%)
BAC   42.18 (+1.18%)
S&P 500   4,440.39 (-0.19%)
DOW   34,706.33 (-0.17%)
QQQ   371.40 (-0.42%)
AAPL   146.14 (-0.47%)
MSFT   297.67 (-0.63%)
FB   347.84 (+0.54%)
GOOGL   2,831.75 (+0.26%)
TSLA   762.69 (+1.20%)
AMZN   3,400.18 (-0.46%)
NVDA   219.18 (-2.51%)
BABA   145.75 (-3.60%)
NIO   35.43 (-1.61%)
CGC   13.96 (-4.12%)
GE   104.04 (+1.05%)
MU   74.37 (+0.45%)
AMD   105.20 (-0.89%)
T   27.20 (+0.04%)
F   13.89 (+1.31%)
ACB   5.97 (-2.93%)
DIS   175.29 (-0.54%)
PFE   44.08 (-0.25%)
BA   221.33 (+0.10%)
BAC   42.18 (+1.18%)
ASX:LCT

Living Cell Technologies Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume76,622 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive LCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Living Cell Technologies and its competitors with MarketBeat's FREE daily newsletter.


About Living Cell Technologies

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Living Cell Technologies (ASX:LCT) Frequently Asked Questions

What stocks does MarketBeat like better than Living Cell Technologies?

Wall Street analysts have given Living Cell Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Living Cell Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Living Cell Technologies' earnings last quarter?

Living Cell Technologies Limited (ASX:LCT) released its quarterly earnings data on Tuesday, February, 19th. The company reported $0.00 earnings per share (EPS) for the quarter.
View Living Cell Technologies' earnings history
.

Who are Living Cell Technologies' key executives?

Living Cell Technologies' management team includes the following people:
  • Dr. Kenneth Taylor, CEO & Exec. Director (Age 77, Pay $357.3k)
  • Mr. Daya Uka, Chief Financial Officer
  • Dr. Janice Lam, Chief Operating Officer
  • Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA, Company Sec. (Age 57)

What other stocks do shareholders of Living Cell Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Living Cell Technologies investors own include eWellness Healthcare (EWLL), Energous (WATT), Cheniere Energy (LNG) and AllianceBernstein Global High Income Fund (AWF).

What is Living Cell Technologies' stock symbol?

Living Cell Technologies trades on the ASX under the ticker symbol "LCT."

How much money does Living Cell Technologies make?

Living Cell Technologies has a market capitalization of $0.00 and generates $268,184.00 in revenue each year.

How many employees does Living Cell Technologies have?

Living Cell Technologies employs 147,000 workers across the globe.

What is Living Cell Technologies' official website?

The official website for Living Cell Technologies is www.lctglobal.com.

How can I contact Living Cell Technologies?

The company can be reached via phone at 61 3 8689 9997.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.